Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly likely to launch weight loss & anti-diabetes drug in India: Is it safe to consume?
Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...
pharmaphorum9d
Lilly says Mounjaro launch is "viral in nature"
Lilly's head of diabetes, Mike Mason ... as well as approval of the new drug as an obesity therapy. The company plans to start a rolling application with the FDA for obesity later this year ...
Eli Lilly plans to expand its pipeline to address obesity-related conditions in India, says top executive
US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...
NBC Los Angeles29d
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
The diabetes counterparts of Wegovy and Zepbound — Ozempic and Mounjaro, respectively — are covered by Medicare and most insurance plans. Both Novo Nordisk and Eli Lilly are studying their ...